AR092348A1 - DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc - Google Patents
DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORcInfo
- Publication number
- AR092348A1 AR092348A1 ARP130102439A ARP130102439A AR092348A1 AR 092348 A1 AR092348 A1 AR 092348A1 AR P130102439 A ARP130102439 A AR P130102439A AR P130102439 A ARP130102439 A AR P130102439A AR 092348 A1 AR092348 A1 AR 092348A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aminocarbonyl
- alkoxy
- several times
- substituted once
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: m es el número 0 ó 1; n es el número 0 ó 1; p es un número de 0 a 3; q es el número de 0, 1 ó 2; r es un número de 1 a 3; A es: un enlace; -(CRʲRᵏ)ₜ-; -C(O)-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-C(O)-; -NRᵃ-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-NRᵃ-; -C(O)NRᵃ-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-NRᵃC(O)-; -O-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-O-; -S-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-S-; -SO₂-(CRʲRᵏ)ₜ-; o -(CRʲRᵏ)ₜ-SO₂-; t es un número de 0 a 4; W es: -CRᵇRᶜ-; -O-; -S-; -SO₂-; o -NRᵈ-; uno de X¹, X², X³ y X⁴ es N y los demás son CRᵉ; o dos de X¹, X², X³ y X⁴ son N y los demás son CRᵉ; o tres de X¹, X², X³ y X⁴ son N y el restante es CRᵉ; o cada uno de X¹, X², X³ y X⁴ es CRᵉ; Y es: -O-; -S-; SO₂-; -CRᶠRᵍ-; o -NRʰ-; Z es: CH; o N; R¹, R², R³, R⁴, R⁵, R⁶, R⁷ y R⁸ con independencia entre sí son: hidrógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; o R³ y R⁴ junto con el átomo al que están unidos pueden formar un grupo etileno; o R³ y R⁴ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o R⁵ y R⁶ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o R⁷ y R⁸ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de R³ y R⁴ junto con uno de R⁵ y R⁶ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de R⁵ y R⁶ junto con uno de R⁷ y R⁸ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; cada R⁹ es con independencia: alquilo C₁₋₆; halógeno; alcoxi C₁₋₆; o ciano; dichos restos alquilo C₁₋₆ pueden estar sin sustituir o sustituidos una o varias veces por halógeno; R¹⁰ es: hidrógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di(alquil C₁₋₆)-aminocarbonilo; ciano; hidroxi-alquilo C₁₋₆; N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-amino-carbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; halógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; R¹¹ es: hidrógeno; halógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di-(alquil C₁₋₆)-aminocarbonilo; (alquil C₁₋₆)-sulfonil-amino; (alquil C₁₋₆)-sulfonil-amino-alquilo C₁₋₆ ciano; hidroxi-alquilo C₁₋₆ N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-aminocarbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; R¹² es: hidrógeno; halógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di-(alquil C₁₋₆) -aminocarbonilo; ciano; hidroxi-alquilo C₁₋₆; N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-aminocarbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; o R¹⁰ y R¹¹ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; Rᵃ, Rᵇ, Rᶜ y Rᵈ con independencia entre sí son: hidrógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; o Rᵇ y Rᶜ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de Rᵇ y Rᶜ junto con uno de R⁷ y R⁸ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de Rᵇ y Rᶜ junto con uno de R⁵ y R⁶ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; cada Rᵉ es con independencia: hidrógeno; alquilo C₁₋₆; halógeno; alcoxi C₁₋₆; o ciano; dichos restos alquilo C₁₋₆ pueden estar sin sustituir o sustituidos una o varias veces por halógeno; Rᶠ es: hidrógeno; halógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; Rᵍ es: hidrógeno; alquilo C₁₋₆; cicloalquilo C₃₋₆; cicloalquenilo C₃₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆; halógeno; (alquil C₁₋₆)-carbonilo; (cicloalquil C₃₋₆)-carbonilo; (cicloalquil C₃₋₆)-(alquil C₁₋₆)-carbonilo; ciano-(alquil C₁₋₆)-carbonilo; hidroxi-(alquil C₁₋₆)-carbonilo; alcoxi C₁₋₆-(alquil C₁₋₆)-carbonilo; carboxi; N-ciano-aminocarbonilo; N-ciano-N-(alquil C₁₋₆)-aminocarbonilo; N-(alquil C₁₋₆)-acetimidamidilo; N,N-di-(alquil C₁₋₆)-acetimidamidilo; N-ciano-N-(alquil C₁₋₆)-acetimidamidilo; N-hidroxi-acetimidamidilo; N-alcoxi C₁₋₆-acetimidamidilo; N-hidroxi-N-(alquil C₁₋₆)-acetimidamidilo; N-(alcoxi C₁₋₆)-N-(alquil C₁₋₆)-acetimidamidilo; 2-nitro-1-N-(alquil C₁₋₆)-amino-vinilo; formilo; (alquil C₁₋₆)-sulfonilo; (cicloalquil C₃₋₆)-sulfonilo; (cicloalquil C₃₋₆)-(alquil C₁₋₆)-sulfonilo; (alquil C₁₋₆)-sulfonil-alquilo C₁₋₆; aminocarbonilo; N-hidroxi-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; aminocarbonil-alquilo C₁₋₆; N-(alquil C₁₋₆)-aminocarbonil-alquilo C₁₋₆; N,N-di-(alquil C₁₋₆)-aminocarbonil-alquilo C₁₋₆; (alcoxi C₁₋₆)-carbonilo; N-hidroxi-N-(alquil C₁₋₆)-aminocarbonilo; N-alcoxi C₁₋₆-N-(alquil C₁₋₆)-aminocarbonilo; N,N-di(alquil C₁₋₆)-aminocarbonilo; aminosulfonilo; N-(alquil C₁₋₆)-aminosulfonilo; N,N-di-(alquil C₁₋₆)-aminosulfonilo; ciano; alcoxi C₁₋₆ (alquil C₁₋₆)-sulfonil-amino; N-(alquil C₁₋₆)-sulfonil-aminocarbonilo; N-(alqui
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670519P | 2012-07-11 | 2012-07-11 | |
US201361788430P | 2013-03-15 | 2013-03-15 | |
US201361837461P | 2013-06-20 | 2013-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092348A1 true AR092348A1 (es) | 2015-04-15 |
Family
ID=48782328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102439A AR092348A1 (es) | 2012-07-11 | 2013-07-10 | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
Country Status (21)
Country | Link |
---|---|
US (1) | US9115101B2 (es) |
EP (1) | EP2872504B1 (es) |
JP (1) | JP6262228B2 (es) |
KR (1) | KR20150029739A (es) |
CN (2) | CN107235867A (es) |
AR (1) | AR092348A1 (es) |
AU (1) | AU2013288756A1 (es) |
BR (1) | BR112015000581A2 (es) |
CA (1) | CA2876449A1 (es) |
CL (1) | CL2014003572A1 (es) |
CO (1) | CO7141456A2 (es) |
CR (1) | CR20140548A (es) |
ES (1) | ES2612165T3 (es) |
HK (2) | HK1208679A1 (es) |
IL (1) | IL236293A0 (es) |
MX (1) | MX2015000325A (es) |
PE (1) | PE20151007A1 (es) |
PH (1) | PH12014502788B1 (es) |
SG (1) | SG11201408534VA (es) |
TW (1) | TW201408652A (es) |
WO (1) | WO2014009447A1 (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI519515B (zh) | 2011-12-21 | 2016-02-01 | 諾維拉治療公司 | B型肝炎抗病毒劑 |
EP3243826B1 (en) | 2012-04-26 | 2019-10-30 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之***酮化合物 |
EA027280B1 (ru) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
BR112015028538A2 (pt) | 2013-05-17 | 2017-07-25 | Janssen Sciences Ireland Uc | derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
KR20160023676A (ko) * | 2013-06-21 | 2016-03-03 | 에프. 호프만-라 로슈 아게 | RORc 조절제로서 아릴 설탐 유도체 |
NO3024819T3 (es) | 2013-07-25 | 2018-07-21 | ||
WO2015027124A1 (en) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JP6458041B2 (ja) * | 2014-01-10 | 2019-01-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | RORcモジュレーターとしてのアリールスルタム誘導体 |
ES2760521T3 (es) * | 2014-01-10 | 2020-05-14 | Hoffmann La Roche | Derivados de aril-sultamo como moduladores de RORc |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2015116904A1 (en) | 2014-02-03 | 2015-08-06 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
RU2702109C1 (ru) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Комбинированная терапия для лечения инфекций вгв |
CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
CN104370755B (zh) * | 2014-08-18 | 2017-04-12 | 江西隆莱生物制药有限公司 | 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法 |
WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
WO2016069496A1 (en) * | 2014-10-26 | 2016-05-06 | Galileo Group, Inc. | Swarm approach to consolidating and enhancing smartphone target imagery by virtually linking smartphone camera collectors across space and time using machine-to-machine networks |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
EP3233849A1 (en) * | 2014-12-17 | 2017-10-25 | F. Hoffmann-La Roche AG | HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
BR112017014770A2 (pt) | 2015-01-08 | 2018-01-16 | Advinus Therapeutics Ltd | compostos bicíclicos, composições e aplicações médicas dos mesmos |
WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017005668A1 (en) * | 2015-07-08 | 2017-01-12 | F. Hoffmann-La Roche Ag | ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
EP3319962B1 (en) * | 2015-07-08 | 2020-05-13 | H. Hoffnabb-La Roche Ag | Aryl sultam derivatives as rorc modulators |
ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
RU2018121946A (ru) | 2015-11-20 | 2019-12-23 | Вайтаи Фармасьютиклз, Ллк | Модуляторы ror-гамма |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
JP7027437B2 (ja) * | 2016-10-27 | 2022-03-01 | エスカリア バイオサイエンシーズ,ビーブイ | ROR-γモジュレーター |
CN106966912B (zh) * | 2017-04-01 | 2019-07-02 | 沧州那瑞化学科技有限公司 | (r)-3-氨基丁醇的制备方法 |
IL271889B2 (en) | 2017-07-10 | 2023-03-01 | Celgene Corp | Antisplit compounds and methods of their use |
MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
WO2019022223A1 (ja) * | 2017-07-28 | 2019-01-31 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3765009A4 (en) * | 2018-03-12 | 2021-11-10 | Escalier Biosciences, BV | BICYCLIC ROR-GAMMA MODULATORS |
US11242350B2 (en) | 2018-03-12 | 2022-02-08 | Escalier Biosciences B.V. | Spirocyclic ROR-gamma modulators |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
IL308122A (en) | 2021-06-16 | 2023-12-01 | Celgene Corp | Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007051810A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
CN101351209A (zh) * | 2005-11-01 | 2009-01-21 | 转化技术制药公司 | 取代的酰胺的药学应用 |
WO2011007819A1 (ja) | 2009-07-17 | 2011-01-20 | 塩野義製薬株式会社 | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 |
EP2368886A1 (en) | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
JP6063870B2 (ja) | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
JP6182594B2 (ja) | 2012-04-27 | 2017-08-16 | グラクソ グループ リミテッドGlaxo Group Limited | 新規化合物 |
-
2013
- 2013-07-10 TW TW102124802A patent/TW201408652A/zh unknown
- 2013-07-10 AR ARP130102439A patent/AR092348A1/es unknown
- 2013-07-11 KR KR20157003144A patent/KR20150029739A/ko not_active Application Discontinuation
- 2013-07-11 PE PE2015000022A patent/PE20151007A1/es not_active Application Discontinuation
- 2013-07-11 EP EP13735278.7A patent/EP2872504B1/en not_active Not-in-force
- 2013-07-11 MX MX2015000325A patent/MX2015000325A/es unknown
- 2013-07-11 US US13/939,962 patent/US9115101B2/en not_active Expired - Fee Related
- 2013-07-11 AU AU2013288756A patent/AU2013288756A1/en not_active Abandoned
- 2013-07-11 ES ES13735278.7T patent/ES2612165T3/es active Active
- 2013-07-11 WO PCT/EP2013/064637 patent/WO2014009447A1/en active Application Filing
- 2013-07-11 CN CN201710559460.1A patent/CN107235867A/zh active Pending
- 2013-07-11 CN CN201380036729.8A patent/CN104470917B/zh not_active Expired - Fee Related
- 2013-07-11 CA CA2876449A patent/CA2876449A1/en not_active Abandoned
- 2013-07-11 JP JP2015520984A patent/JP6262228B2/ja not_active Expired - Fee Related
- 2013-07-11 SG SG11201408534VA patent/SG11201408534VA/en unknown
- 2013-07-11 BR BR112015000581A patent/BR112015000581A2/pt not_active IP Right Cessation
-
2014
- 2014-11-28 CO CO14262762A patent/CO7141456A2/es unknown
- 2014-12-01 CR CR20140548A patent/CR20140548A/es not_active Application Discontinuation
- 2014-12-15 PH PH12014502788A patent/PH12014502788B1/en unknown
- 2014-12-15 IL IL236293A patent/IL236293A0/en unknown
- 2014-12-30 CL CL2014003572A patent/CL2014003572A1/es unknown
-
2015
- 2015-09-24 HK HK15109405.3A patent/HK1208679A1/xx not_active IP Right Cessation
-
2018
- 2018-03-23 HK HK18104078.7A patent/HK1244781A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014009447A1 (en) | 2014-01-16 |
PH12014502788A1 (en) | 2015-02-09 |
MX2015000325A (es) | 2015-04-14 |
ES2612165T3 (es) | 2017-05-12 |
CN104470917A (zh) | 2015-03-25 |
CN104470917B (zh) | 2017-08-04 |
EP2872504A1 (en) | 2015-05-20 |
SG11201408534VA (en) | 2015-02-27 |
KR20150029739A (ko) | 2015-03-18 |
CA2876449A1 (en) | 2014-01-16 |
PE20151007A1 (es) | 2015-06-29 |
HK1208679A1 (en) | 2016-03-11 |
US20140031330A1 (en) | 2014-01-30 |
JP6262228B2 (ja) | 2018-01-17 |
TW201408652A (zh) | 2014-03-01 |
CO7141456A2 (es) | 2014-12-12 |
BR112015000581A2 (pt) | 2017-06-27 |
CL2014003572A1 (es) | 2015-04-24 |
PH12014502788B1 (en) | 2015-02-09 |
CR20140548A (es) | 2015-02-12 |
US9115101B2 (en) | 2015-08-25 |
CN107235867A (zh) | 2017-10-10 |
EP2872504B1 (en) | 2016-11-16 |
IL236293A0 (en) | 2015-02-26 |
HK1244781A1 (zh) | 2018-08-17 |
JP2015522057A (ja) | 2015-08-03 |
AU2013288756A1 (en) | 2015-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092348A1 (es) | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc | |
AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
AR088793A1 (es) | Compuestos y metodos para mejorar las respuestas inmunitarias innatas | |
ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
DOP2010000272A (es) | Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion | |
CR20160578A (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR095164A1 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |